PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15314206-6	2004	In this study, we used a triplex-forming oligonucleotide (TFO) to selectively inhibit Ets2 transcription in prostate cancer cells.	tfo	58-61	ETS proto-oncogene 2, transcription factor	Homo sapiens	86-90	
15314206-7	2004	We had previously shown that the Ets2-targeting TFO, which was directed to a unique purine-rich sequence critical for Ets2 promoter activity, acted with a high degree of sequence-specificity and target selectivity.	tfo	48-51	ETS proto-oncogene 2, transcription factor	Homo sapiens	33-37	
15314206-7	2004	We had previously shown that the Ets2-targeting TFO, which was directed to a unique purine-rich sequence critical for Ets2 promoter activity, acted with a high degree of sequence-specificity and target selectivity.	tfo	48-51	ETS proto-oncogene 2, transcription factor	Homo sapiens	118-122	
15314206-8	2004	TFO-mediated downregulation of Ets2 in prostate cancer cells induced important phenotypic changes, including inhibition of anchorage-dependent and anchorage -independent growth, cell cycle alterations and induction of apoptotic cell death.	tfo	0-3	ETS proto-oncogene 2, transcription factor	Homo sapiens	31-35	
15314206-9	2004	Expression of Ets2 under the control of a heterologous promoter abolished the anti-proliferative effects of the TFO in both short- and long-term assays, suggesting that these effects were a direct result of downregulation of Ets2 transcription and confirming target selectivity of the TFO.	tfo	112-115	ETS proto-oncogene 2, transcription factor	Homo sapiens	14-18	
15314206-9	2004	Expression of Ets2 under the control of a heterologous promoter abolished the anti-proliferative effects of the TFO in both short- and long-term assays, suggesting that these effects were a direct result of downregulation of Ets2 transcription and confirming target selectivity of the TFO.	tfo	112-115	ETS proto-oncogene 2, transcription factor	Homo sapiens	225-229	
15314206-9	2004	Expression of Ets2 under the control of a heterologous promoter abolished the anti-proliferative effects of the TFO in both short- and long-term assays, suggesting that these effects were a direct result of downregulation of Ets2 transcription and confirming target selectivity of the TFO.	tfo	285-288	ETS proto-oncogene 2, transcription factor	Homo sapiens	14-18	
15314206-13	2004	Furthermore, the activity and selectivity of the Ets2-targeting TFO suggest that it might represent a valid approach to prostate cancer therapy.	tfo	64-67	ETS proto-oncogene 2, transcription factor	Homo sapiens	49-53	
12560478-2	2003	In this study, we designed a triplex-forming oligonucleotide (TFO) directed to a homopurine:homopyrimidine sequence in the Ets2 promoter.	tfo	62-65	ETS proto-oncogene 2, transcription factor	Homo sapiens	123-127